Stay updated with breaking news from High Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of promising early pipeline New,...
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock Next generation anthracycline,...
/PRNewswire/ -- The "Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)),...